Clinical Trials Browser

Phase 1/2 × Neoplasms, Plasma Cell × ruxolitinib × Clear all

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1/2 Completed

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell